Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

1.390 +0.020 (+1.46%)
Streaming Delayed Price Updated: 3:53 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Telomir Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
InvestorNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Reports Favorable IND-Enabling GLP Safety Results for Telomir-1
Via Investor Brand Network
News headline image
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Via ACCESS Newswire
News headline image
TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death ↗
HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity in this aggressive human model, the company said. 
Via Stocktwits
Why Telomir Pharmaceuticals Stock Is Rising 40% Premarket Today ↗
Via Stocktwits
News headline image
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Via ACCESS Newswire
News headline image
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Thursday's after hours session: top gainers and losers ↗
Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug ↗
Telomir Pharmaceuticals' stock rises as Telomir-1 shows strong lab results against aggressive triple-negative breast cancer cells. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are moving before the opening bell on Thursday? ↗
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Via ACCESS Newswire
News headline image
Why Richardson Electronics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
What's going on in today's after hours session ↗
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics. 
Via Chartmill
News headline image
Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Via ACCESS Newswire
News headline image
Stock Market Today: Dow Jones, Nasdaq Futures Slip Amid Delay In Trade Deficit Data During Shutdown—Trilogy Metals, AMD, Applovin In Focus ↗
U.S. stock futures fell on Tuesday following Monday’s mixed moves. Futures of major benchmark indices were lower. 
Via Benzinga
Topics Stocks
News headline image
Why Telomir Pharmaceuticals Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
News headline image
McCormick, Telomir Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday ↗
U.S. stock futures mixed, key stocks to watch: MKC, SNWV, PENG, TELO, SAR. Check out premarket coverage. Cramer warns on chip stock. 
Via Benzinga
News headline image
What's Behind The Sharp 39% After-Hours Rally In Telomir Pharmaceuticals? ↗
Telomir's stock jumped nearly 39% in after-hours trading following news that its lead compound, Telomir-1, showed potential in reversing cancer-related DNA changes in aggressive prostate cancer... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Wondering what's happening in today's after-hours session? ↗
Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. 
Via Chartmill
News headline image
Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Via ACCESS Newswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.